Clinical Trials Sponsored by Lexigen Pharmaceuticals

Total 20208 results

Lexicon Pharmaceuticals

Recruiting

A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) (PROGRESS)

Diabetic Peripheral Neuropathic Pain

United States
Lexicon Pharmaceuticals

Completed

Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia (RELIEF-PHN1)

Postherpetic Neuralgia

United States, Czechia, Poland
Lexicon Pharmaceuticals

Completed

Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function

Healthy | Renal Impairment

United States
Lexicon Pharmaceuticals

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Carcinoid Syndrome

United States
Lexicon Pharmaceuticals

Completed

A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects

Drug-drug Interaction

United States
Lexicon Pharmaceuticals

Completed

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Carcinoid Syndrome

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Canada, Israel
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Primary Open-angle Glaucoma

United States
Lexicon Pharmaceuticals

Completed

DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

Healthy

United States
Lexicon Pharmaceuticals

Completed

DDI Study With Multiple-dose LX4211 and Single Dose Digoxin

Healthy

United States
Lexicon Pharmaceuticals

Completed

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Lexicon Pharmaceuticals

Completed

A Thorough QT Study of Telotristat Etiprate

QT Interval

United States
Lexicon Pharmaceuticals

Completed

A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

Drug Interactions

United States
Lexicon Pharmaceuticals

Completed

An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

Drug Interactions

United States
Lexicon Pharmaceuticals

Completed

Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects

Healthy

United States
Lexicon Pharmaceuticals

Completed

Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

Healthy

United States
Lexicon Pharmaceuticals

Completed

Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

Efficacy, Safety, and PK of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1)

Diabetes | Diabetic Peripheral Neuropathy

United States
Lexicon Pharmaceuticals

Completed

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms (TELEPATH)

Carcinoid Syndrome

United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom
Lexicon Pharmaceuticals

Completed

Telotristat Etiprate for Carcinoid Syndrome Therapy (TELECAST)

Carcinoid Syndrome

United States, Australia, Belgium, Canada, France, Germany, Israel, Spain, Sweden, United Kingdom, Netherlands
Lexicon Pharmaceuticals

Unknown

Oral Contraceptive DDI Study

Healthy

United States
Lexicon Pharmaceuticals

Completed

An Open-Label Food Effect Study of Telotristat Etiprate

Healthy

United States
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Healthy Subjects

United States
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Type 2 Diabetes Mellitus | Renal Impairment

United States
Lexicon Pharmaceuticals

Completed

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects (AME)

Healthy

United States
Lexicon Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Lexicon Pharmaceuticals

Completed

An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects

Irritable Bowel Syndrome

United States
Lexicon Pharmaceuticals

Completed

Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate

Rheumatoid Arthritis

United States, Bulgaria, Czech Republic, Hungary, Poland, Serbia
Lexicon Pharmaceuticals

Completed

Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment

Age-Related Memory Disorders

Netherlands
Lexicon Pharmaceuticals

Completed

A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

United States, Lithuania, Poland, Slovakia
Lexicon Pharmaceuticals

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Carcinoid Syndrome

Germany, United Kingdom
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

Hepatic Impairment

United States
Lexicon Pharmaceuticals

Completed

PK Study of Sotagliflozin in Subjects With Hepatic Impairment

Healthy | Hepatic Impairment

United States
Lexicon Pharmaceuticals

Completed

Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects

Drug Interactions

United States
Lexicon Pharmaceuticals

Completed

Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

Healthy

United States
Lexicon Pharmaceuticals

Completed

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males (LX1606-104)

Carcinoid Syndrome

United Kingdom
Lexicon Pharmaceuticals

Completed

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

Healthy

United States
Lexicon Pharmaceuticals

Completed

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals

Completed

Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Lexicon Pharmaceuticals

Completed

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

Type 2 Diabetes Mellitus

United States, Canada, Mexico
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy (SOTA-GLIM)

Type 2 Diabetes Mellitus

United States, Bulgaria, Hungary, Slovakia
Lexicon Pharmaceuticals
Sanofi

Terminated

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure

Cardiac Failure Aggravated

United States, Canada, Netherlands
Lexicon Pharmaceuticals
Sanofi

Terminated

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED)

Heart Failure | Chronic Kidney Diseases | Type 2 Diabetes Mellitus

Estonia, Belgium, Sweden, Italy, China, United States, Canada, Bulgaria, Chile, Denmark, Hungary, Latvia, Mexico, Russian Federation, Serbia, Spain, Portugal, Romania, Turkey, Poland, Lithuania, Argentina, Australia, Brazil, Czechia, France, Georg... and more
Lexicon Pharmaceuticals
Sanofi

Terminated

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

Heart Failure | Type 2 Diabetes Mellitus

Belgium, Canada, Israel, Spain, Germany, Argentina, Chile, Hungary, Korea, Republic of, Latvia, Lithuania, Russian Federation, Sweden, Romania, Poland, Brazil, Denmark, United States, Australia, Austria, Czechia, Finland, France, Greece, Ita... and more
Lexicon Pharmaceuticals
Sanofi

Completed

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control (SOTA-CKD3)

Type 2 Diabetes Mellitus | Chronic Kidney Disease Stage 3

United States, Argentina, Brazil, Canada, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine
Lexicon Pharmaceuticals
Sanofi

Terminated

Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (SOTA-BONE)

Type 2 Diabetes Mellitus

United States, Australia, Canada, Korea, Republic of, Mexico, New Zealand, Russian Federation, Taiwan
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin (SOTA-EMPA)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czechia, France, Italy, Latvia, Mexico, Russian Federation, Slovakia, Spain, United Kingdom

3

Subscribe